Asklepios BioPharmac
Asklepios BioPharmaceutical, Inc. Announces Former Portfolio Company’s Preclinical Asset for Duchenne Muscular Dystrophy Has Advanced into the Clinic
25 avr. 2018 08h05 HE | Asklepios BioPharmaceutical, Inc.
Pfizer, Inc. Dosed First Patient in its Mini-Dystrophin Gene Therapy Phase 1b Trial Another AskBio Platform Product to be Acquired by Big Pharma Novartis CHAPEL HILL, N.C., April 25, 2018 (GLOBE...